Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Sep 20, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Drug Sensitivity Testing in Osteosarcoma: A Case Report.

Ines Lohse^1,2,3,4, Giselle Dutcher⁵, Hassan Al-Ali^5,6,7

¹Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

Current Oncology (Toronto, Ont.)

|May 27, 2025

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Role of AXL Signaling and Mutant <i>Isocitrate Dehydrogenase 1/2</i> in Conventional Chondrosarcoma.

Cancers·2026

Same author

Lumbar intrathecal catheterization in rats targeting the cerebral cortex: a drug delivery method and validation.

bioRxiv : the preprint server for biology·2026

Same author

Development of NanoBRET cellular target engagement assays in primary neurons for activating mutants of p21-activated kinase 1.

bioRxiv : the preprint server for biology·2026

Same author

Trustworthy artificial intelligence in predictive medicine: cancer survival analysis using ethical-by-design and explainable artificial intelligence models.

JAMIA open·2026

Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4.

Molecular cancer therapeutics·2026

Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026

Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026

Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026

Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026

Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026

Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026

See all related articles

This summary is machine-generated.

Ex-vivo drug sensitivity testing (DST) shows promise for guiding cancer treatment. In a pediatric osteosarcoma case, DST accurately predicted response to standard therapy, demonstrating its clinical utility.

Area of Science:

Oncology
Precision Medicine
Pharmacology

Background:

Precision medicine aims to tailor cancer treatments to individual patients.
Ex-vivo drug sensitivity testing (DST) offers a method for personalized treatment selection.
Osteosarcoma, particularly in pediatric cases, presents challenges due to limited effective treatment options.

Observation:

A pediatric osteosarcoma patient underwent DST alongside standard-of-care treatment.
The DST identified sensitivity to anthracyclines and methotrexate, key components of the MAP regimen.
Clinical outcomes and pathology confirmed sensitivity to the MAP treatment, with 90% tumor necrosis.

Findings:

DST is technically feasible and can be completed within a clinically relevant timeframe.

Keywords:

drug sensitivity testing osteosarcoma precision medicine

More Related Videos

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Sep 20, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

The testing provides personalized drug sensitivity data for available agents.

DST results correlated with the patient's clinical response to therapy.

Implications:

DST can supplement existing stratification methods by providing tumor-specific drug response data.
This approach can aid in treatment selection for rare cancers like osteosarcoma.
The findings support the integration of DST into clinical decision-making for improved cancer care.